Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.
Fangda assists Brattea in completing its high-value series-D financing
2024 / 04 / 24
READ MORE
2026 / 01 / 29
Fangda Advises Leading Clean Energy Key Materials Company Zhenshi on Its Successful Listing on the SSE Main Board
2026 / 01 / 21
Fangda Advises VeriSilicon on Acquiring Controlling Stake in Pixelworks Semiconductor
2026 / 01 / 19
Fangda Advises Raynovent on Licensing Agreement with Qilu Pharmaceutical for GLP-1/GIP Dual-Target Ultra-Long-Acting Agonist RAY1225 Injection
2026 / 01 / 14
Fangda Advises Sino Biopharmaceutical on Its Acquisition of 100% Equity Interests in Hygieia
2026 / 01 / 07
Fangda Advises on the World’s First Compliant Carbon Coin Issuance
